Advanced Integrative Platforms for Cellular Immunotherapies Against Resistant Hematopoietic Malignancies and Solid Tumors
Abstract
Cell therapy is a powerful means of cancer treatment; however, currently existing cell therapies face major challenges in refractory or resistant hematological cancers and solid tumors. Our central hypothesis is that an interdisciplinary, convergent science approach is essential to advance cell-based immunotherapies against cancer. Here, we are building of a convergent science consortium across three major institutions as three different research sites (Yale, Johns Hopkins University, and Mt. Sinai) to perform an integrated set of synergistic research activities. We will combine multiple scientific disciplines such as CRISPR gene editing, bioengineering, cancer biology, molecular and cell biology, immunology, immunotherapy, cell therapy, animal model, computational science, genetics and genomics, and clinical science to bring groundbreaking transformations to cell therapy across multiple cancer types. Our consortium project will focus on addressing the Overarching Challenge of Therapeutics - Advance Immunotherapy across the different Peer Reviewed Cancer Research Program (PRCRP) Topic Areas, and perform a unifying set of research across at least three different fiscal year 2022 PRCRP Topic Areas, including blood cancers, brain cancers, and colon cancer. This project will build the infrastructure of a multisite, multi-institute consortium to develop the next generation of better and safer cellular immunotherapies. It will get us ready for a full-blown consortium for the next-stage translational and clinical development of these new cellular therapeutics. While the initial efforts focus on building the framework and initiating the research, subsequent translational and clinical development of these new therapeutics have the potential to achieve better treatment outcome and thereby benefit cancer patients in the longer run. The success of this consortium will contribute significantly to advancing the vision of the PRCRP to decrease the burden of multiple types of cancer. Large populations of the American public, including active-duty Service Members, Veterans, and other military beneficiaries suffer from cancer, including blood cancers, brain cancers, lymphoma, and colon cancer. Developing new treatment options against one or more forms of these cancers will have a broad impact to the society, benefiting people including in military Service Members, Veterans, their Family Members, as well as the broader public.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Jan 04, 2024
- Source ID
- HT94252310860
Entities
People
- Sidi Chen
Organizations
- United States Army
- Yale University